Related Experiment Videos
Treatment of patients with recurrent primary brain tumors with AZQ
Abstract:
We have evaluated the efficacy of intravenous 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (diaziquone or AZQ, NSC-182986) in the treatment of recurrent primary anaplastic brain tumors. Three of 16 evaluable patients (18.8%) showed clinical and radiographic improvement that permitted discontinuation of corticosteroids, 4 patients (25%) showed either clinical or radiographic improvement and were considered partial responders, and 9 patients (56.2%) showed no effects after two courses of AZQ. The treatment was well tolerated, and hematologic toxicity was mild. Pharmacokinetic studies indicated rapid decay of the parent compound from plasma using two different infusion schedules. These results compare favorably with those obtained using the nitrosoureas or procarbazine as single agents.
Insights
Diaziquone (AZQ) showed moderate efficacy in treating recurrent anaplastic brain tumors, with some patients experiencing significant improvement. The treatment was well-tolerated with mild toxicity, offering a potential alternative to traditional therapies.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Anaplastic brain tumors are aggressive and often recur.
- Current treatments like nitrosoureas and procarbazine have limitations.
- Diaziquone (AZQ) is an investigational chemotherapeutic agent.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous diaziquone (AZQ) for recurrent primary anaplastic brain tumors.
- To compare AZQ's outcomes with existing single-agent therapies.
Main Methods:
- A clinical trial involving patients with recurrent anaplastic brain tumors.
- Intravenous administration of diaziquone (AZQ) using two different schedules.
- Assessment of clinical and radiographic responses, corticosteroid discontinuation, and toxicity.
- Pharmacokinetic analysis of AZQ plasma levels.
Main Results:
- 18.8% of patients showed significant improvement allowing corticosteroid discontinuation.
- 25% of patients achieved partial response (clinical or radiographic improvement).
- 56.2% of patients showed no response to AZQ.
- AZQ was well-tolerated with mild hematologic toxicity.
- Rapid plasma decay of AZQ was observed.
Conclusions:
- Diaziquone (AZQ) demonstrates a degree of efficacy in recurrent anaplastic brain tumors.
- AZQ presents a favorable safety profile compared to some established agents.
- Further investigation into AZQ's therapeutic potential in neuro-oncology is warranted.